FDA approves Wegovy weight-loss shot for heart disease patients - including ... trends now
View
comments
Obese and overweight adults could now get a Wegovy prescription to reduce their risk of a heart attack or stroke.
The FDA approved the treatment for this use in non-diabetic adults today after large-scale studies showed the drug slashed their risk of the complications by up to 28 percent.
The agency added that Wegovy — which uses semaglutide — should be used alongside a low-calorie diet and increased levels of physical activity.
Shares in the drug's owner Novo Nordisk surged to $566billion yesterday, making it the 12th most valuable company in the world, after it revealed a new medication that could prompt weight loss twice as fast as Ozempic.
The FDA approved the medication for this use in non-diabetic patients today, following clinical trials which showed it cut the risk by up to 28 percent
Wegovy — which uses the drug semaglutide — was already approved for use in overweight or obese
